LUPIN has acquired 60% stake in Pharma Dynamics, a South African
generic marketing firm, for an undisclosed amount. This
acquisition—fifth in 12 months—gives Lupin a foothold into the South
“We are looking at creating strong footholds in various markets to register sales of $1 billion by the year end. This year we have allocated Rs 250 crore for R&D and we expect our growth to be more than 40%,” Lupin chairman D B Gupta said. Pharma Dynamics is the sixth-largest generic player in South Africa. It recorded sales of Rand 118 million (nearly $15 million) for the year ended February 2008. It had an EBITA of over 20%.
It sells tuberculosis products in South Africa through a partnership with Aspen and concentrates more on branded generics. The pharmaceutical market in South Africa is estimated to be $2.5 billion, of which the generics segment contributes $700-800 million. “We plan to capture 50-60% of the generics market in the next few years,” Lupin MD Kamal Sharma said.
Lupin also plans to use Pharma Dynamics to expand sales to other African nations at a later stage. Lupin is looking at expanding its presence in the Middle East, Japan, Eastern Europe and North America.
As Indians we know India in itself is an amazing nation and even the world agrees with that, however, grass is always greener on the other side and that is why Indians desire to immigrate a More
Helplinelaw can set up your session with quality and experienced lawyers to discuss and resolve your legal matters. You can avail consultation in form of sending questions, phone call or webchat discussion More